Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human TNFSF11 Antibodies:
anti-Mouse (Murine) TNFSF11 Antibodies:
anti-Rat (Rattus) TNFSF11 Antibodies:
Go to our pre-filtered search.
Human Monoclonal TNFSF11 Primary Antibody for ChIP, FACS - ABIN252476
Kikuchi, Matsuguchi, Tsuboi, Mitani, Tanaka, Matsuoka, Yamamoto, Hishikawa, Noguchi, Yoshikai: Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. in Journal of immunology (Baltimore, Md. : 1950) 2001
Show all 20 Pubmed References
Human Polyclonal TNFSF11 Primary Antibody for IF (p), IHC (p) - ABIN672696
Yang, Li, Yang, Shen, Zou, Zhu, Zhang, Yang, Li: Efficacy and safety of echinacoside in a rat osteopenia model. in Evidence-based complementary and alternative medicine : eCAM 2013
Show all 12 Pubmed References
Human Monoclonal TNFSF11 Primary Antibody for ChIP, CyTOF - ABIN252546
Hsu, Lacey, Dunstan, Solovyev, Colombero, Timms, Tan, Elliott, Kelley, Sarosi, Wang, Xia, Elliott, Chiu, Black, Scully, Capparelli, Morony, Shimamoto, Bass, Boyle: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. in Proceedings of the National Academy of Sciences of the United States of America 1999
Show all 10 Pubmed References
Human Polyclonal TNFSF11 Primary Antibody for IF (p), IHC (p) - ABIN668556
Zhang, Liu, Li, Bai: Mycobacterium tuberculosis 10-kDa co-chaperonin regulates the expression levels of receptor activator of nuclear factor-?B ligand and osteoprotegerin in human osteoblasts. in Experimental and therapeutic medicine 2015
Show all 9 Pubmed References
Human Monoclonal TNFSF11 Primary Antibody for ELISA - ABIN4249074
Pearse, Sordillo, Yaccoby, Wong, Liau, Colman, Michaeli, Epstein, Choi: Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. in Proceedings of the National Academy of Sciences of the United States of America 2001
Show all 9 Pubmed References
Human Monoclonal TNFSF11 Primary Antibody for FACS, IHC (fro) - ABIN252684
Yoneda, Ishimaru, Arakaki, Kobayashi, Izawa, Moriyama, Hayashi: Estrogen deficiency accelerates murine autoimmune arthritis associated with receptor activator of nuclear factor-kappa B ligand-mediated osteoclastogenesis. in Endocrinology 2004
Show all 3 Pubmed References
Human Monoclonal TNFSF11 Primary Antibody for CyTOF, FACS - ABIN4361916
Shetty, Pepin, Charest, Perron, Doyle, Voisine, Dagenais, Pibarot, Mathieu: Expression of bone-regulatory proteins in human valve allografts. in Heart (British Cardiac Society) 2006
Show all 3 Pubmed References
Mouse (Murine) Monoclonal TNFSF11 Primary Antibody for IHC (fro), FACS - ABIN2479510
Andersen, Jørgensen, Bardram, Hilsted: Screening for multiple endocrine neoplasia type 1 in patients with recognized pituitary adenoma. in Clinical endocrinology 1991
Show all 4 Pubmed References
Human Polyclonal TNFSF11 Primary Antibody for IHC, IHC (p) - ABIN4361905
Lim, Liu, Hunter, Cheng, Mah, Helms: Downregulation of Wnt causes root resorption. in American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics 2014
Show all 2 Pubmed References
main finding is that OPG (show TNFRSF11B Antibodies) levels decreased significantly during 8 weeks of alcohol abstinence.
Studies showed that the central hypothalamic-pituitary regulatory system, via it's relative hormones, seems to control OPG/RANKL/RANK system function, and the pulsatility and circadian rhythmicity of these hormones may induce an oscillatory fluctuation of the OPG/ RANKL ratio. Also, psycological characteristics may provoke a shift of the OPG/ RANKL ratio towards an unbalanced or a balanced status. [review]
Studies strongly implicates RANK and RANKL as key molecules involved in the initiation of BRCA1-associated breast cancer. [review]
RANK is frequently expressed by cancer cells in contrast with RANKL which is frequently detected in the tumor microenvironment, and together they participate in every step in cancer development. (Review)
Proinsulin (show INS Antibodies) C-peptide prevents a reduction of type I collagen expression and decreases, in combination with insulin (show INS Antibodies), receptor activator of nuclear factor-kappaB (RANKL) levels.
The RANKL/OPG ratio significantly increased in the presence of bone metastasis with appropriate sensitivity and specificity (73% and 72%, respectively) at a cutoff of >/=0.14 for the detection of bone metastasis. Serum OPG (show TNFRSF11B Antibodies) and RANKL/OPG ratios are promising biomarkers for detecting bone metastasis in breast cancer patients.
Correlations between sRANKL and IL-18 (show IL18 Antibodies) in BALF.
RANK/RANKL signaling is involved in the androgen deprivation therapy-induced acceleration of bone metastasis in castration-insensitive prostate cancer and is inhibited by osteoprotegerin (show TNFRSF11B Antibodies) to prevent bone metastasis.
This study suggested that RANKL could be a marker to differentiate between pagetoid squamous cell carcinoma in situ and extramammary Paget disease .
TNF-alpha-converting enzyme (show ADAM17 Antibodies) -mediated cleavage of soluble RANKL from activated lymphocytes, especially B cells, can promote osteoclastogenesis in periodontitis.
loss of BMP signaling specifically in osteocytes dramatically increases bone mass presumably through simultaneous inhibition of RANKL and SOST (show SOST Antibodies), leading to osteoclast inhibition and Wnt (show WNT2 Antibodies) activation together.
The potentiation of RANKL induced CTX release by dexamethasone was significantly less in bone marrow macrophage cells from mice with conditional knockout of the osteoclastic glucocorticoid receptor (show NR3C1 Antibodies) and completely absent in cells from GR(dim) mice, which carry a point mutation in one dimerizing interface of the GC receptor.
findings demonstrate that mTORC1 activation-stimulated RANKL expression in B cells is sufficient to induce bone loss and osteoporosis. The study also established a link between mTORC1 and the RANKL/OPG axis via negative regulation of beta-catenin (show CTNNB1 Antibodies).
dihydroartemisinin inhibited RANKL-induced NF-kappaB (show NFKB1 Antibodies) and NFAT (show NFATC1 Antibodies) activity.
Cyanidin chloride is capable of inhibiting osteoclast formation, hydroxyapatite resorption and RANKL-induced signal pathways in vitro and ovariectomy-induced bone loss in vivo.
Together these data indicate that osteocyte apoptosis plays a central and controlling role in triggering osteocyte RANKL production and the activation of new resorption leading to bone loss in disuse.
matrine abrogated RANKL-induced activation of NF-kappaB (show NFKB1 Antibodies), AKT (show AKT1 Antibodies), and MAPK (show MAPK1 Antibodies) pathways and suppressed osteoclastogenesis-related marker expression, including matrix metalloproteinase 9 (show MMP9 Antibodies), NFATc1 (show NFATC1 Antibodies), TRAP, C-Src (show SRC Antibodies), and cathepsin K (show CTSK Antibodies)
The anti-osteoclastic and anti-resorptive actions of Luteoloside are mediated via blocking NFATc1 (show NFATC1 Antibodies) activity and the attenuation of RANKL-mediated Ca(2 (show CA2 Antibodies)+) signaling as well as NF-kappaB (show NFKB1 Antibodies) and MAPK (show MAPK1 Antibodies) pathways.
Osteoprotegerin (show TNFRSF11B Antibodies) facilitates pulmonary arterial hypertension pathogenesis by regulating pulmonary arterial smooth muscle cell proliferation via integrin alphavbeta3 (show ITGAV Antibodies)/FAK (show PTK2 Antibodies)/AKT (show AKT1 Antibodies) signaling pathway.
results demonstrate that IL-15 (show IL15 Antibodies) and RANKL induce osteoclastogenesis synergistically, and IL-15 (show IL15 Antibodies) might play a novel and major role in destructive inflammatory bone diseases
This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found.
TNF-related activation-induced cytokine
, osteoclast differentiation factor
, osteoprotegerin ligand
, receptor activator of nuclear factor kappa B ligand
, receptor activator of nuclear factor kappa-B ligand
, tumor necrosis factor ligand superfamily member 11
, tumor necrosis factor (ligand) superfamily, member 11
, Receptor activator of nuclear factor kappa-B ligand
, OPG ligand
, receptor activator of NF-kappaB ligand
, tumor necrosis factor-related activation-induced cytokine
, TNF superfamily member 11 L homeolog
, tumor necrosis factor superfamily member 11 L homeolog